Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

158.56 -2.08 (-1.29%)
Official Closing Price Updated: 6:30 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,625,167
Open 159.97
Bid (Size) 158.35 (5)
Ask (Size) 158.90 (4)
Prev. Close 160.64
Today's Range 158.05 - 160.00
52wk Range 143.13 - 175.97
Shares Outstanding 2,628,679,824
Dividend Yield 3.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Unusual Options Activity For July 29
Via Benzinga
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
From Johnson & Johnson
Via Business Wire

Performance

YTD
-0.88%
-0.88%
1 Month
+8.48%
+8.48%
3 Month
+8.00%
+8.00%
6 Month
-0.50%
-0.50%
1 Year
-5.35%
-5.35%

More News

Read More
Stocks Going Ex Dividend In August 2024
Via Talk Markets
7 Long-Term Stocks to Buy on the Dip: July 2024
Via InvestorPlace
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Check Out What Whales Are Doing With JNJ
Via Benzinga
Why the dividend investor may take a look at NYSE:JNJ.
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
From Beasley Allen Law Firm
Via Business Wire
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
From Ad Hoc Group of Counsel
Via Business Wire
3 Stocks Reeling From Ruined Reputations: Can They Recover?
Via InvestorPlace
3 Beaten-Down Value Stocks Poised for a Massive Comeback: July 2024
Via InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Via Benzinga
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Via Benzinga
Exposures Product Safety
Biden's Exit From Presidential Race 'Yet Another Curveball For Equity Investors': Analysts
Via Benzinga
Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan
From Beasley Allen Law Firm
Via Business Wire
Four Stocks To Watch This Week - Monday, July 22
Via Talk Markets
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Via Benzinga
Johnson & Johnson Faces Legal Hurdle In Talc Lawsuit Battle
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Stocks See Mixed Reactions Amid Geopolitical Tensions And Earnings Surprises
Via Talk Markets
Topics Government
Exposures Political
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
Via The Motley Fool
Topics ETFs
MarketBeat Week in Review – 7/15 - 7/19
Via MarketBeat
Topics Economy
Exposures Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.